A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 785 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure... June 23, 2025 Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... April 5, 2023 Load more HOT NEWS New Combination of Old Drugs Improves Survival in Patients with Prostate... EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab How could proposed changes to data protection laws affect research? Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local...
